FluoSphera Expands Human-Based Preclinical Platform with €1.23M Funding
FluoSphera's Funding Achievement
FluoSphera, a Swiss biotech startup focusing on drug safety and efficacy testing, has successfully raised €1.23 million (CHF 1.15 million). This funding round was led by Soulmates Ventures and included participation from a Swiss business angel and IndieBio New York. FluoSphera's aim is to enhance its human-based preclinical platform, which is vital in predicting drug efficacy and safety.
The Importance of Accurate Preclinical Models
The drug development process is long and costly, with a significant number of drug candidates failing during clinical trials. A major contributing factor to these failures is that existing preclinical models do not always effectively predict how candidates will perform in human trials. FluoSphera's innovative approach seeks to fill this gap, thus reducing the risk involved in drug development.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.